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Abstract
Endothelial dysfunction is critically involved in the pathogenesis of
pulmonary arterial hypertension (PAH) and that exogenously
administered microRNA may be of therapeutic benefit. Lower
levels of miR-483 were found in serum from patients with idio-
pathic pulmonary arterial hypertension (IPAH), particularly those
with more severe disease. RNA-seq and bioinformatics analyses
showed that miR-483 targets several PAH-related genes, including
transforming growth factor-b (TGF-b), TGF-b receptor 2 (TGFBR2),
b-catenin, connective tissue growth factor (CTGF), interleukin-1b
(IL-1b), and endothelin-1 (ET-1). Overexpression of miR-483 in ECs
inhibited inflammatory and fibrogenic responses, revealed by the
decreased expression of TGF-b, TGFBR2, b-catenin, CTGF, IL-1b, and
ET-1. In contrast, inhibition of miR-483 increased these genes in
ECs. Rats with EC-specific miR-483 overexpression exhibited
ameliorated pulmonary hypertension (PH) and reduced right
ventricular hypertrophy on challenge with monocrotaline (MCT) or
Sugen + hypoxia. A reversal effect was observed in rats that
received MCT with inhaled lentivirus overexpressing miR-483.
These results indicate that PAH is associated with a reduced level
of miR-483 and that miR-483 might reduce experimental PH by
inhibition of multiple adverse responses.
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Introduction
Pulmonary arterial hypertension (PAH) is a multifaceted vascular
disease resulting from functional changes and structural remodeling
in small pulmonary arteries (Hoeper et al, 2013). In patients with
PAH and various animal models with experimental pulmonary
hypertension (PH), endothelial dysfunction is linked to increased
production of vasoconstrictors, pro-inflammatory cytokines, and
growth factors together with attenuated production of vasodilators
(Schermuly et al, 2011). The current drug therapy for PAH, includ-
ing bosentan, sildenafil, macitentan, riociguat, prostacyclin, and its
derivatives, aims to target pathways related to endothelin-1 (ET-1),
nitric oxide, and vasoconstrictor prostaglandins (Galie et al, 2016a,b).
However, these agents improve quality of life and longevity but are
not curative. MicroRNAs (miRNAs) modulate gene expression by
inhibiting translation or inducing degradation of target mRNA tran-
scripts. New therapeutic approaches involving miRNA therapeutics
are emerging that either mimic or inhibit miRNAs (Janssen et al,
2013).
MicroRNA-483 (miR-483), containing both miR-483-3p and miR-
483-5p (hereafter referred to as miR-483-3p/-5p), are intronic
miRNAs that are encoded together with insulin-like growth factor 2
1 Cardiovascular Research Center, School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center, Key Laboratory of Environment and Genes Related to
Diseases, Ministry of Education of China, Xi’an Jiaotong University, Xian, China
2 State Key Laboratory of Cardiovascular disease & FuWai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
3 Department of Medicine, University of California, San Diego, La Jolla, CA, USA
4 Department of Cardiology, First Affiliated Hospital, Xi’an Jiaotong University, Xian, China
5 Department of Pediatrics (Cardiology), Cardiovascular Institute and Wall Center for Pulmonary Vascular Diseases, Stanford University School of Medicine, Stanford,
CA, USA
6 Department of Geriatric Medicine, Qilu Hospital of Shandong University, Jinan, China
7 Department of Epidemiology and Health Statistics, School of Public Health, Xi’an Jiaotong University, Xian, China
8 Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan
9 Warshel Institute for Computational Biology, School of Life and Health Sciences, The Chinese University of Hong Kong, Shenzhen, China
10 Department of Cardiology & Key Lab of Pulmonary Vascular Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union
Medical College, Beijing, China
*Corresponding author. Tel: +86 1069 155023; E-mail: jingzhicheng@vip.163.com
**Corresponding author. Tel: +1 858 534 3736; E-mail: jshyy@ucsd.edu
†These authors contributed equally to this work as first authors
ª 2020 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 12: e11303 | 2020 1 of 13
(IGF2) (Li et al, 2015). The sequences of miR-483-3p/-5p are highly
conserved among mammalian species including human, mouse, and
rat. MiR-483 targets the 30UTR of connective tissue growth factor
(CTGF), platelet-derived growth factor-b (PDGF-b), tissue inhibitor
of metalloproteinase 2, and Smad4, a key component protein in the
transforming growth factor b (TGF-b) signaling pathway (Li et al,
2014; Anderson & McAlinden, 2017; He et al, 2017). Additionally,
miR-483 suppresses the growth and proliferation of several cell
types by downregulating extracellular signal-regulated kinase 1,
mitogen-activated protein kinase-activated protein kinase 2, Yes-
associated protein 1, and IGF1 (Bertero et al, 2011; Wang et al,
2012; Ni et al, 2013). With respect to endothelial biology, we previ-
ously showed that miR-483 enhances endothelial cell (EC) function,
in part via its anti-fibrogenic effect and a recent report by others
shows that disturbed flow decreases miR-483 level in ECs (He et al,
2017; Fernandez Esmerats et al, 2019).
Based on this conceptual framework, we sought to test the
hypothesis that miR-483 is pathophysiologically important in PH
and that it may be useful as a disease biomarker and a therapeutic
target. In the current study, we investigated whether low levels of
miR-483 were associated with idiopathic PAH (IPAH). Our results
show that the levels of circulating miR-483 were indeed lower in
IPAH patients and seemed to correlate inversely with the severity of
clinical manifestations. Experimental validation revealed that miR-
483 targeted multiple genes including TGF-b, interleukin 1b (IL-1b),
and ET-1 in ECs. Rats with miR-483 overexpression in the endothe-
lium were PH-protected. Of translational relevance, intratracheal
administered miR-483 reversed monocrotaline (MCT)-induced PH in
rats, which provides therapeutic potential of miR-483.
Results
Decreased miR-483 level in human IPAH patients
We first examined the circulatory levels of miR-483-3p/-5p in a
cohort of IPAH patients (patient demographics and clinical charac-
teristics in Table 1). Compared to age- and sex-matched healthy
controls (HCs), the circulating levels of miR-483-3p/-5p were signif-
icantly lower in IPAH patients (Fig 1A). The receiver operating
characteristic (ROC) curves shown in Fig 1B reveal that patients
with miR-483-3p and miR-483-5p levels < 27% and 26% of those in
HCs might have PAH, with sensitivity 88.4% and 82.1%; specificity
56.8% and 48.9% (area under the ROC curve, 0.77 and 0.66, respec-
tively). According to the new PAH risk stratification for prognosis
and initial therapy (2018 World Symposium on Pulmonary Hyper-
tension; Galie et al, 2019), we divided IPAH patients into low-,
intermediate-, and high-risk groups with estimated 1-year mortality
risks of < 5%, 5–10%, and > 10%, respectively. Of note, miR-483-
3p level was lower in intermediate- and high-risk than low-risk
patients (Fig 1C).
Patients with various forms of PAH, including IPAH, have
higher serum or plasma levels of ET-1 and IL-6 (Schermuly
et al, 2011). In the present study, the serum levels of ET-1 and
IL-6 in the IPAH cohort were also significantly higher than
those in control groups (Appendix Fig S1A and B) with areas
under the ROC curve 0.74 and 0.74, respectively (Appendix Fig
S1C and D). Interestingly, the serum levels of ET-1 and IL-6
seemed to be inversely correlated with those of miR-483-3p
(Fig 1D).
Table 1. Clinical characteristics of PAH patients and control subjects.
Serum CD144-EVs
Control (n = 95) IPAH (n = 139) Control (n = 34) IPAH (n = 37)
Sex [female, n (%)] 77 (81%) 117 (84%) 3 (82%) 5 (86%)
Age (years) 33 (21–47) 32 (17–70) 37 (20–46) 35 (23–40)
Functional class [n (%)]
I – 3 (2%) – 2 (5%)
II – 21 (42%) – 16 (43%)
III – 23 (49%) – 16 (43%)
IV – 4 (7%) – 3 (8%)
CI (l/min/m2) – 2.3  0.6 – 2.2  0.5
PVR (Wood U) – 14.1  6.2 – 14.2  6.2
mPAP (mmHg) – 60.0  17.2 – 58.7  15.5
RAP (mmHg) – 8.1  4.8 – 7.9  5.0
SvO2 (%) – 66.5  8.7 – 66.2  8.1
NT-proBNP (ng/l) – 1683  2348 – 1933  2393
6MWD (m) – 444.5  102.7 – 436.9  102.7
Medication [n (%)]
ERA – 67 (48.2%) – 22 (59.5%)
PDE5 inhibitor – 79 (56.8%) – 27 (73.0%)
Epoprostenol – 26 (18.7%) – 7 (18.9%)
2 of 13 EMBO Molecular Medicine 12: e11303 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Jin Zhang et al
miR-483 targets PAH-related genes and pathways in endothelium
We postulated that the lower levels of miR-483-3p/-5p in IPAH
patient sera were linked to their decreased expression in pulmonary
endothelium. To confirm this notion, we isolated CD144 (VE-
cadherin, an EC marker)-enriched extracellular vesicles (EVs) from
serum of IPAH patients and HCs. As illustrated in Fig 2A, miR-483-
3p/-5p content was lower in CD144-enriched EVs from IPAH than
HC. The lower levels of miR-483 found in circulation and CD144-
enriched EVs of IPAH patients suggested that the expression of miR-
483-3p/-5p might affect genes and pathways involved in PAH.
We conducted RNA-seq analysis to examine the transcriptomes
in cultured human pulmonary arterial ECs (PAECs) overexpressing
miR-483. As illustrated in Fig 2B and Appendix Fig S2, gene ontol-
ogy (GO) analysis of differentially regulated pathways showed that
miR-483 was correlated with negative regulation of Wnt signaling
and inflammatory response, TGF-b receptor signaling, cell adhesion,
response to hypoxia, apoptotic processes, oxidation–reduction
processes, and negative regulation of cell migration and prolifera-
tion. Such changes in transcriptomes suggested that miR-483-3p/-5p
could affect the EC phenotype. The heatmap shown in Fig 2C
revealed that miR-483 overexpression downregulated genes
involved in cell proliferation, migration, inflammation, Wnt and
TGF-b receptor signaling, apoptosis process, response to hypoxia,
and oxidative stress. In contrast, genes (e.g., COL4A2) involved in
cell adhesion (Rhodes et al, 2015) were upregulated. Data illustrated
in Fig 2 suggest that elevated miR-483-3p/-5p inhibits PAH-related
genes and pathways in the pulmonary endothelium.
miR-483 targets TGF-b, TGFBR2, IL-1b, and ET-1 mRNAs
We then used RNAhybrid software to predict miR-483-targeted
mRNAs. As illustrated in Fig 3A, while miR-483-3p was predicted to
target the 30UTR of TGF-b, TGFbR2, Smad2, ROCK1, b-catenin, and
ET-1 mRNAs, miR-483-5p targets the 30UTR of TGF-b, TGFBR2,
Smad2, Smad3, IL-1b, and ET-1 mRNAs. Additionally, miR-483 target-
ing 30UTR of TGF-b, TGFBR2, IL-1b, and ET-1 mRNAs was found
conserved among human, rat, and mouse (Appendix Table S1). To
validate the in silico predictions, pre-miR-483 was overexpressed in
human PAECs by lentivirus (Lenti-miR-483, Fig 3B). As predicted, the
mRNA and protein levels of TGF-b, TGFBR2, b-catenin, CTGF, IL-1b,
and ET-1 were lower in PAECs infected with Lenti-miR-483 (Fig 3C
and D). In the complementary approach, miR-483 inhibition by anti-
miR-483 resulted in increased mRNA and protein levels of TGF-b,
TGFBR2, b-catenin, CTGF, IL-1b, and ET-1 (Appendix Fig S3A–C). We
then examined whether miR-483-3p/-5p directly targets these genes
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Figure 1. Lower serum miR-483 level in IPAH patients.
A Serum levels of miR-483-3p/-5p in IPAH patients (n = 139) and HC (n = 95) measured by qPCR. The data are fold change normalized to the averaged level of HC.
B ROC curve with sensitivity and specificity of serum levels of miR-483-3p/-5p for differentiating IPAH patients from HCs at diagnosis (IPAH, n = 139; HC, n = 95).
C Levels of miR-483-3p/-5p associated with PAH risk in three groups. IPAH patients were divided into a low-risk group (Low) and an intermediate- plus high-risk group
(Inter&high) according to the World Symposium on Pulmonary Hypertension 2018 [14].
D Levels of miR-483-3p were inversely correlated with serum levels of ET-1 (IPAH, n = 118; HC, n = 95) and IL-6 (IPAH, n = 112; HC, n = 93).
Data information: Values are expressed as median  interquartile range. Statistical test: Mann–Whitney U-test (A), Kruskal–Wallis U-test (C).
Source data are available online for this figure.
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by using TGF-b, TGFBR2, IL-1b, and ET-1 30UTR constructs conju-
gated with a luciferase reporter. As shown in Fig 3E, miR-483 overex-
pression decreased the luciferase activity of the wild-type reporters
Luc-TGF-b (WT), Luc-TGFBR2 (WT), Luc-IL-1b (WT), and Luc-ET-1
(WT). However, no reduction of luciferase activity was observed in
ECs transfected with Luc-TGF-b (mut), Luc-TGFBR2 (mut), Luc-IL-1b
(mut), or Luc-ET-1 (mut) in which the miR-483-targeted sequences
were mutated. Moreover, miR-483-3p/-5p levels were increased in the
miR-induced silencing complexes (miRISC) (i.e., Ago1, Ago2) in
PAECs overexpressing miR-483 (Fig 3F). Additionally, levels of TGF-
b, TGFBR2, b-catenin, CTGF, IL-1b, and ET-1 mRNAs were also
increased in association with Ago1 and Ago2 (Fig 3G), indicating
these mRNAs were targeted by miR-483 in the miRISC.
PH amelioration in EC-miR-483-Tg rats
With the findings of reduced miR-483 level in circulation and PAECs
of IPAH patients and that miR-483 targeted several PAH-related
genes in cultured PAECs, we investigated whether a supraphysiolog-
ical level of miR-483 mitigates experimental PH in rat models by
generating a transgenic rat line with miR-483 expression driven by
the VE-cadherin promoter (i.e., EC-miR-483-Tg). As expected, levels
of miR-483-3p/-5p were higher in lung ECs from EC-miR-483-Tg rats
than wild-type littermates (Fig 4A). A comparison of miR-483-3p/-5p
levels in aortic ECs and peripheral blood mononuclear cells con-
firmed the EC-specific miR-483 overexpression (Appendix Fig S4).
Consistently, miR-483 levels were elevated in CD144-enriched EVs
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Figure 2. MiR-483 targets PAH-related genes and pathways in PAECs.
A CD144-enriched EVs were isolated from serum of IPAH patients (n = 37) and HCs (n = 34). The levels of miR-483-3p/-5p were measured by qPCR.
B, C PAECs were transfected with miR-483-3p/-5p mimic or scramble RNA for 36 hr before RNA isolation and then analyzed by RNA-seq. Data are results from two
biological repeats. (B) PAH-related GO enrichment delineated by DAVID for the top 300 upregulated or downregulated genes with the cutoff of P < 0.05. (C) Heat
map comparison of log2 fold changes of the indicated genes.
Data information: Values are expressed as median  interquartile range. Statistical test: Mann–Whitney U-test.
Source data are available online for this figure.
4 of 13 EMBO Molecular Medicine 12: e11303 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Jin Zhang et al
in serum collected from EC-miR-483-Tg rats (Fig 4B), which
suggests that these miRNAs were derived from endothelium.
We cultured lung ECs isolated from EC-miR-483-Tg and control
wild-type rats under hypoxic conditions. Hypoxia increased the
proliferation and migration of ECs from wild-type ECs but not those
from EC-miR-483-Tg rats (Fig 4C and D). The basal protein and
mRNA levels of TGF-b, TGFBR2, b-catenin, CTGF, IL-1b, and ET-1
in the lung homogenates in EC-miR-483-Tg rats were similar to or
slightly lower than that in their wild-type littermates (WT+saline vs.
Tg+saline in Fig 4E). MCT administration induced these PAH-related
genes to much higher levels in the wild-type than those in EC-miR-
483-Tg rats (WT+MCT vs. Tg+MCT in Fig 4E). Interestingly, circula-
tion and lung levels of miR-483-3p/-5p were lower in wild-type rats
receiving MCT, when compared to EC-miR-483-Tg rats receiving
MCT (Fig 4F). For miR-483 targeting, Ago1 and Ago2 miRISC
complexes isolated from the lung homogenates of EC-miR-483-Tg
rats treated with or without MCT were associated with increased
miR-483-3p, miR-483-5p, along with TGF-b, TGFBR2, b-catenin,
CTGF, IL-1b, and ET-1 mRNAs (Fig 4G and H). The PH-associated
changes in mean PAP (mPAP) and the Fulton index (right ventricle
weight to left ventricle plus interventricular septum weight, i.e.,
RV/LV+S) were ameliorated in EC-miR-483-Tg rats given MCT
(Fig 5A and B). Vascular thickening and lumen closure seen in the
wild-type rats receiving MCT were mitigated in EC-miR-483-Tg
littermates with MCT administration (Fig 5C). Additionally, Evans
blue dye staining showed increased permeability of endothelium in
MCT-treated wild-type lungs, which was less severe in EC-miR-483-
Tg lungs with MCT treatment (Fig 5D). For loss-of-function
A B C
D
E F G
Figure 3. MiR-483-targeted genes.
A Predicted binding sites for miR-483-3p/-5p on the 30UTR of mRNAs as indicated.
B–D PAECs were infected with Lenti-pre-miR-483 or Lenti-null for 24 hr. Expression levels of miR-483-3p/-5p, TGF-b, TGFBR2, b-catenin, CTGF, IL-1b, and ET-1 mRNA
and protein were measured by qPCR and Western blot, respectively.
E Bovine aortic ECs were transfected with a luciferase reporter fused with the 30UTR of TGF-b (Luc-TGF-b WT), TGFBR2 (Luc-TGFBR2 WT), IL-1b (Luc-IL-1b WT), or
ET-1 (Luc-ET-1 WT) or a binding site mutation (Luc-TGF-b Mut, Luc-TGFBR2 Mut, Luc-IL-1b Mut, ET-1-Mut), then infected with Lenti-pre-miR-483 for additional
36 hr. Luciferase activity was measured.
F, G PAECs were infected with Lenti-pre-miR-483 or Lenti-null for 36 h. The Ago1- or Ago2-associated miRNAs and mRNAs were enriched by immunoprecipitation with
anti-Ago1 or anti-Ago2. Levels of miR-483-3p/-5p and TGF-b, TGFBR2, b-catenin, CTGF, IL-1b, and ET-1 mRNA were detected by qPCR and normalized to those of
Ago1 or Ago2 protein.
Data information: Values are expressed as mean  SEM from three independent experiments. Statistical test: t-test (*P < 0.05 between the indicated groups, exact
P-values are shown in Appendix Table S3).
Source data are available online for this figure.
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experiments, we administered locked nucleic acid (LNA)-modified
antisense miR-483 (LNA-483) to MCT-treated rats. Compared with
control rats receiving scramble RNA, the levels of miR-483 in sera
and lung were decreased, while the mRNA and protein levels of
PAH-related genes (e.g., TGF-b, TGFBR2, b-catenin, CTGF, IL-1b,
and ET-1) were upregulated in rats having LNA-483 (Appendix Fig
S5A–C). These results suggest that miR-483 could downregulate
PAH-related genes in experimental PH rats. With respect to pheno-
typic changes, mPAP, Fulton index, and pulmonary arterial remod-
eling were also exacerbated by LNA-anti-483 administration
(Appendix Fig S5D–F).
The beneficial effect of miR-483 on mitigating experimental PH
was also demonstrated in the SU5416/hypoxia-induced PH model.
The onset of PH, as revealed by increased mPAP and Fulton index,
E
B C DA
HF
G
Figure 4. Decreased level of PAH-induced genes in EC-miR-483 Tg rats.
A Lung ECs were isolated from EC-miR-483 transgenic rats (Tg) and their wild-type littermates (WT), n = 3 in each group. MiR-483-3p/-5p levels were measured by qPCR.
B Serum from WT and Tg rats (n = 6) was collected. MiR-483-3p and miR-483-5p associated with CD144 were enriched by immunoprecipitation with anti-CD144.
Levels of miR-483-3p/-5p were measured by qPCR.
C, D Lung ECs isolated from miR-483-Tg rat and WT littermates were exposed to normoxia or hypoxia (0.2% O2) for 24 hr. Proliferation and migration of ECs were
measured by flow cytometry and wound healing assay, respectively.
E–H Tg and WT rats were injected with saline or MCT. Expression levels of TGF-b, TGFBR2, b-catenin, CTGF, IL-1b, and ET-1 mRNA and protein in lung tissues
were measured by qPCR and Western blot, respectively (E). Levels of miR-483-3p/-5p in serum and lung tissues were measured by qPCR (F). Ago1- or
Ago2-associated miRNAs (G) and mRNAs (H) were enriched from the isolated lung tissues by immunoprecipitation with anti-Ago1 or anti-Ago2 and
quantified by qPCR (n = 3×3, samples were pooled from three animals for each assay, and 3 independent experiments [a total of 9 animals] were
performed).
Data information: Values are expressed as mean  SEM. Data are representative of three independent experiments (C, D). Statistical test: t-test (*P < 0.05 vs. respective
controls or between the indicated groups, exact P-values are shown in Appendix Table S3).
Source data are available online for this figure.
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tended to be attenuated in EC-miR-483-Tg rats versus wild-type rats,
both with SU5416/hypoxia treatment (Fig 5E and F). Consistently,
circulation and lung levels of miR-483 were reduced (Appendix Fig
S6A), while TGF-b, TGFBR2, b-catenin, CTGF, IL-1b, and ET-1
mRNAs and protein levels in lung tissues were increased in Su5416/
hypoxia-treated WT rats but not in EC-miR-483-Tg rats
(Appendix Fig S6B and C).
Intratracheal administration of miR-483 reduces
PH susceptibility
To test the efficacy of exogenously administered miR-483 to allevi-
ate PH, we delivered miR-483 to rats via inhalation of Lenti-miR-
483-GFP. Following intratracheal administration (Fig 6A), the circu-
latory and pulmonary levels of miR-483-3p/-5p were significantly
higher in rats receiving Lenti-miR-483-GFP versus Lenti-GFP (Fig 6B
and C). The efficacy of the lentivirus administration was further
demonstrated by flow cytometry showing the presence of GFP in the
lungs of rats that received the lentivirus (Appendix Fig S7).
Lenti-miR-483-GFP administration attenuated the MCT induction of
TGF-b, TGFBR2, b-catenin, CTGF, IL-1b, and ET-1 (Fig 6D) and
reversed the MCT-induced PH (Fig 6E and F). Neither MCT nor
Lenti-miR-483-GFP affected systemic blood pressure in the 3 groups
(Fig 6G). The protective effect of miR-483 in attenuating PH is also
supported by comparing RV enlargement (i.e., RV/LV, Fig 6H) and
vessel thickness and occlusion (Fig 6I). In line with the mitigated
PH, Lenti-miR-483-GFP administration seemed to improve the
survival of MCT-administered rats (Fig 6J). Overall, the results in
Fig 6 suggest that exogenously administered miR-483 reversed
MCT-induced PH in rat models.
Discussion
Data from IPAH patients, PH rat models, and cultured PAECs
provide evidence that low miR-483 is associated with propensity
to disease and that elevated levels are protective. We show that
miR-483 targets the 30-UTR of multiple genes implicated in PAH,
including those involved in TGF-b signaling (e.g., TGF-b,
TGFBR2), inflammation (e.g., IL-1b), and vasoconstriction (e.g.,
ET-1). Given PAH risk stratification is critical for initial therapy
strategy and prognosis evaluation (Galie et al, 2019), here we
show that lower circulating levels of miR-483 among IPAH
patients had worse prognosis (Fig 1C). Thus, the novelty of our
observations is that miR-483 provides a unifying factor that can
address multiple adverse responses associated with PAH.
Lower levels of miR-483 in lung ECs isolated from PH rats
(Appendix Fig S8) were coincident with increased expression of
PAH-related genes (e.g., ET-1). Thus, an optimal level of miR-483 in
pulmonary endothelium may mitigate PAH-related EC dysfunction.
Indeed, miR-483 overexpression in cultured PAECs induced the
expression of genes critical for EC homeostasis that include
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Source data are available online for this figure.
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M+GFP, and M+483).
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Source data are available online for this figure.
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Kru¨ppel-like factor 2 (KLF2), KLF4, eNOS, ACE2, and APLNR
(Appendix Fig S9; Shen et al, 2009; Alastalo et al, 2011; Huang
et al, 2017; Zhang et al, 2018). Interestingly, KLF4 overexpression,
statins treatment, and pulsatile shear stress, known to enhance
endothelial function, also increase the expression of miR-483 in ECs
(He et al, 2017; Fernandez Esmerats et al, 2019). As an intronic
miRNA, miR-483 is co-expressed with IGF2. However, IGF2 has not
been implicated in PAH, unlike other growth factors such as TGF-b,
VEGF, IGF-1, and PDGF. Thus, the mechanism underlying PAH
attenuation of miR-483 via IGF2 in pulmonary endothelium warrants
further study.
Levels of miR-483-3p/-5p were reduced in the serum, lung
ECs, and CD144-enriched EVs from IPAH patients and PH rats
(Fig 2A, Appendix Fig S10). Thus, decreased miR-483 in CD144-
enriched EVs may be due to decreased miR-483 expression in
the damaged endothelium. It can also be expected that EC-
derived miRNAs are released into the subendothelium and taken
up by vascular smooth muscle cells (VSMCs; Zhu et al, 2017).
The level of miR-483 was indeed increased in the tunica media
of the pulmonary artery in EC-miR-483-Tg rats and in pulmonary
arterial SMCs co-cultured with lung ECs isolated from EC-miR-
483-Tg rats (Appendix Fig S11), suggesting that EC-derived miR-
483 suppresses SMC proliferation and inflammation.
Besides miR-483, other miRNAs have been implicated in PAH
(Kim et al, 2013; Rothman et al, 2016). Among reported miRNAs
involved in PAH, miR-483 is significant because miR-483 level
was inversely correlated with the severity of clinical manifesta-
tions and miR-483 targets multiple genes involved in PAH. Other
than TGF-b, TGFBR2, b-catenin, CTGF, IL-1b, and ET-1 mRNA,
hsa-miR-483-3p is likely to target Smad2, ROCK1, IL-6, IGF1R,
MMP9, NOTCH3, and PP2A, whereas hsa-miR-483-5p targets
Smad2, Smad3, IL-6, NOTCH3, and ACVR1 (Appendix Fig S12).
Moreover, many genes downregulated by miR-483, shown in
Fig 2D, do contain miR-483-3p/-5p target sites in their 30-UTR
(Appendix Fig S13). To our knowledge, none of the reported
miRNA can target PAH as comprehensively as miR-483.
Data illustrated in Fig 1 reveal that serum levels of miR-483-3p
better correlate with clinical features of PAH, when compared to
miR-483-5p. During miRNA processing, the mature miRNA strand of
the miRNA:miRNA* duplex is selectively incorporated into the
miRISC for mRNA targeting, whereas the miRNA* strand degrades
due to its exclusion from the miRISC complex (Khvorova et al,
2003). It is likely that miR-483-3p is the mature strand and miR-483-
5p the miRNA* strand. This thesis is supported by that qPCR Ct
values for miR-483-3p levels in ECs, human and rat serum, and
miRISC (i.e., Ago1, Ago2) were several cycles lower than those of
miR-483-5p (Appendix Fig S14). Hence, miR-483-3p might be more
therapeutically effective.
Clinically, epoprostenol, PDE5 inhibitors, and endothelin receptor
antagonists are limited in their efficacy as phenotypic modulators of
altered vascular function. In this study, intratracheal delivery of
miR-483 at 3 weeks after MCT administration reduced mPAP, RV
hypertrophy, and vascular remodeling (Fig 6). In line with this
finding, the supraphysiological level of miR-483 in EC-miR-483-Tg
rats led to a PH-resistant phenotype (Fig 5). Our findings herein
demonstrate the potential use of exogenously administered miR-483
or agents that elevate endogenous miR-483 to maintain functional
endothelium, at least during the early stages of PAH.
Materials and Methods
Human subjects and serum sampling
In total, 139 IPAH patients were prospectively enrolled from June
2015 to February 2018 at FuWai Hospital, Chinese Academy of
Medical Sciences. Patients diagnosed with IPAH met the published
guidelines for the diagnosis of pulmonary hypertension (Galie et al,
2016a,b), i.e., mPAP ≥ 25 mmHg at rest, pulmonary artery wedge
pressure ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 3
Wood units (Galie et al, 2008). Patients were excluded if associated
with a definite cause, including connective tissue disease, congenital
heart disease, chronic pulmonary thromboembolism, and PAH due
to left heart disease, lung diseases, and hypoxemia. A group of 95
age- and sex-matched healthy subjects were recruited from FuWai
Hospital as well. The investigation conformed to the principles
outlined in the Declaration of Helsinki and the Department of Health
and Human Services Belmont Report. The study protocol was
approved by the ethics committees of FuWai Hospital, and written
informed consent was obtained from all subjects. Blood samples
were drawn from the cubital vein within 1 week from the time of
right heart catheterization. Blood samples were taken from IPAH
patients or healthy subjects in the fasting state for approximately
12 h. None of the individuals had exercise before blood collection.
After centrifugation at 1,500 g for 10 min, the serum was aliquoted
into separator tubes, quickly frozen in liquid nitrogen, and stored at
80°C until use. The experiments were approved by Ethics Commit-
tee of Xi’an Jiaotong University (No. 2018-544).
Serum ET-1 and IL-6 levels
Serum ET-1 and IL-6 levels were measured by ELISA (Abcam, R&D
Systems, respectively), according to the manufacturer’s instructions.
Briefly, serum samples were diluted 1:4 and then incubated in pre-
coated plates. After 30-min incubation with horseradish peroxidase-
labeled secondary antibody, TMB substrate solution was added.
After another 30-min incubation, stop buffer was added and plates
were read immediately by using a microplate reader set at 450 nm
(Infinite M200 Pro, Tecan).
CD144-enriched EVs
CD144-enriched EVs were isolated as described with modifi-
cations (Shang et al, 2017). Briefly, CD144-enriched EVs were
immunoprecipitated from human or rodent serum (1 ml) by
immunoprecipitation (IP) with anti-CD144 antibody (Santa Cruz
Biotechnology) (1 lg per sample) incubating with Dynabeads
(Invitrogen). IgG was used as an isotype control of IP. Total
RNA from CD144-enriched EVs was isolated with TRIzol and
with Caenorhabditis elegans miR-39 (Cel-miR-39) added at 2 nM
as a spike-in control.
Library preparation, RNA-sequencing, and data analysis
Pulmonary arterial endothelial cells were transfected with an
equimolar of miR-483-3p and miR-483-5p mimic or control
mimic (10 nM, Thermo Fisher Scientific) for 36 h, and total
RNA was extracted with TRIzol (Invitrogen). RNA libraries were
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prepared by using the NEBNext Ultra RNA Library Prep Kit
(Illumina) following the manufacturer’s protocols. The cluster-
ing of the index code samples was performed on a cBot Cluster
Generation System with the TruSeq PE Cluster Kit v3-cBot-HS
(Illumina) and sequenced on an Illumina HiSeq platform. Raw
sequencing data (reads) in fastq format were processed with
custom-made Perl scripts that removed reads containing adaptor
poly-N and low-quality sequences. Clean data were then
mapped to the hg19 whole genome by using Hisat2 v2.0.5
(Pertea et al, 2016). Feature Counts v1.5.0-p3 was used to
count the reads numbers mapped to each gene (Liao et al,
2014). Then, reads per kilobase of exon per megabase of
library size (RPKM) were calculated based on the length of the
gene and reads count mapped to this gene, which assembles
transcripts and their abundances, and estimates for gene expres-
sion levels. Differential expression analysis of two groups was
performed by using the DESeq2 R package (Love et al, 2014).
GO enrichment analysis was performed by DAVID to identify
differentially regulated pathways between two groups (Jiao
et al, 2012).
EC-specific miR-483 transgenic rats
EC-miR-483-Tg rats were generated by the Nanjing Biomedical
Research Institute of Nanjing University. Briefly, the mouse 2.5-kb
Cdh5 promoter and rat full length of pre-miR-483 sequence were
cloned by PCR from C57BL/6 mouse and Sprague-Dawley (SD) rat
genomic DNA, respectively. The 0.4-kb rabbit beta globin polyA
was derived from the plasmid pCAG-Cre-GFP. EC-miR-483-Tg
founder rats were generated by pronuclear injection of fertilized
eggs of outbred rats. Pups of EC-miR-483-Tg and their WT litter-
mates were generated by crossing with SD rats. Eight- to 12-week-
old male Tg rats and their age-matched WT littermates were used
for all experiments.
Rat PH models
Animal experiments were approved by the Institutional Animal
Ethics Committee of Xi’an Jiaotong University (No.
XJTULAC2014.212). SD rats were purchased from Xi’an Jiaotong
University Experimental Animal Center. All rodent models were
kept on a 12-h light/dark cycle and fed ad libitum with chow diet
at temperature of 22°C. Male rats (300–350 g body weight) were
administrated MCT (60 mg/kg; Sigma) or equal volume of saline
by subcutaneous injection (Schermuly et al, 2005; Savai et al,
2014). At 21 or 28 days after MCT injection, rats were given
Lenti-GFP or Lenti-miR-483-GFP orotracheally (Savai et al, 2014).
Briefly, rats were anesthetized. Then, curved blunted-ended
forceps were used to grasp the tongue to gain visualization of the
larynx. The lentivirus (1 × 109 PFU), diluted in 100 ll sterile PBS,
was instilled using a PE-10 tubing inserted into the trachea. For
Sugen/hypoxia plus reoxygenation-induced PH model, male rats
(300–350 g) were subcutaneously injected with the vascular
endothelial growth factor receptor inhibitor SU5416 (Sigma-
Aldrich) at 20 mg/kg body weight and housed under hypoxic
conditions (10% O2) for 3 weeks. Rats were then exposed to
normoxia for 2 weeks (reoxygenation). Rats receiving DMSO for
the same durations were negative controls (Schermuly et al,
2005). Animals were randomized for interventions. Rats were
euthanized by pentobarbital sodium before measurement of
hemodynamics. For assessing RV hypertrophy, RV was dissected
and weighed. We used picture scale plate to measure the thick-
ness of pulmonary arteries (20–70 lm in diameters, n = 10 for
each rat). The external diameter (Dex) and inner diameter (Din) of
each artery were measured, and then, the wall thickness was
assessed using (DexDin)/Dex × 100%. The ratio of right ventricle
weight to left ventricle plus interventricular septum weight (RV/
LV+S; i.e., Fulton index) was assessed. Researchers were blinding
for measurement of hemodynamics, Fulton index, and wall thick-
ness, but aware which intervention group corresponded to which
cohort of animals when analyzed the data.
Cell culture
Pulmonary arterial endothelial cell and the EGM-2 BulletKit medium
were obtained from Lonza. Bovine aortic ECs (BAECs) and human
embryonic kidney 293T (HEK293T) cells were obtained from ATCC.
Cells were tested for Mycoplasma contamination. Rat pulmonary
arterial smooth muscle cells (PASMCs) were isolated as described
(Schermuly et al, 2005; Savai et al, 2014). PASMCs, BAECs, and
HEK293T cells were cultured in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum and 100 U/ml
penicillin–streptomycin. PAECs with passages 4–7 were used for all
cell culture experiments. All cells were cultured at 37°C in 5% CO2
and 95% relative humidity.
Rat lung EC isolation
Primary rat lung ECs were isolated as described (Lim & Luscin-
skas, 2006). Briefly, rat lungs were isolated from various groups
of rats and perfused with 20 ml sterile PBS. The minced lung
tissues were transferred to 50-ml tubes containing 15 ml 96%
type I collagenase (Abcam) and incubated at 37°C with gentle
agitation for 45 min. Cell suspensions were filtered through 70-
lm cell strainers (Thermo Fisher Scientific) after 12 trituration
cycles with 20-ml syringes. The cell suspension was washed and
further precipitated with anti-CD31 (Abcam) pre-conjugated Dyna-
beads (Invitrogen).
Wound healing assay
Lung ECs were plated in 6-well plates. Wounds were created with a
200-ll pipette tip through the cells when they were about 90% conflu-
ence. Then, cells were cultured in normoxia or hypoxia (0.2% O2).
Images of cells were taken using microscopy (Olympus) at 0 (W0), 6
(W6), and 12 h (W12) postwounding. The areas were randomly
selected, and widths of wounded areas were measured. Migration was
calculated by (W6W0)/W0 × 100% and (W12W0)/W0 × 100%.
Luciferase reporter plasmids, transfection, and luciferase assay
The 30 untranslated region (30UTR) of human TGF-b, TGFBR2, IL-
1b, and ET-1 gene containing the putative miR-483 targeting sites
was synthesized by Shanghai Personal Biotechnology and subcloned
into the pmirGLO dual-luciferase miRNA target expression vector
(Promega) to obtain Luc-TGF-b-30UTR-WT, Luc-TGFBR2-30UTR-WT,
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Luc-IL-1b-30UTR-WT, and Luc-ET-1-30UTR-WT reporter constructs.
Mutant constructs were further created with “GTGATCGC” to
“GGGGTGGC” replacement in Luc-TGF-b-30UTR-mut; “AGAG-
GAGTG” to “TAGTACTAT” in Luc-TGFBR2-30UTR-mut; “CTGTTGT
CT” to “CAGTAGACA” in Luc-IL-1b-30UTR-mut; and “GGAGTG” to
“GCAATC” in Luc-ET-1-30UTR-mut. The various reporter constructs
were transfected into BAECs by using Lipofectamine 2000 (Invitro-
gen). The luciferase activity was measured by using the Dual-Glo
Luciferase Reporter Assay Kit (Promega) with a luciferase reader
(PerkinElmer).
Ago1-IP and Ago2-IP
Ago1-IP and Ago2-IP were performed as described (He et al, 2017).
Briefly, PAECs or homogenized lung tissues were lysed in a buffer
containing 50 mmol/l Tris–HCl pH 7.5, 150 mmol/l NaCl, 0.1% NP-
40, 1 mmol/l EDTA, and 100 U/ll RNase inhibitor. An amount of
1 ml lysates was incubated overnight with 100 ll protein G Dyna-
beads conjugated with 5 ll anti-Ago1 (Wako Chemicals) or anti-
Ago2 (Cell Signaling Technology) at 4°C. The immunoprecipitated
RNAs were then extracted with TRIzol. A complete list of primers
used for Ago1-IP and Ago2-IP is in Appendix Table S2.
RT–qPCR and Western blot analysis
RNA was extracted from cultured cells by using TRIzol. For serum
samples, RNA was isolated by using TRIzol LS from 200 ll serum.
Cel-miR-39 was added at 2 nM as a spike-in control. Relative mRNA
or miRNA expression was determined by using SYBR Green (Bio-
Rad) or TaqMan probe-participated qPCRs, GAPDH and U6 served
as internal controls for normalization of mRNA and miRNA expres-
sion, respectively. The sequences for qPCR primers are listed in
Appendix Table S2. Proteins were isolated by using RIPA lysis buffer
and separated by SDS–PAGE. After being transferred to PVDF
membranes, membranes were incubated with various antibodies as
indicated. Protein bands were detected by electrochemilumines-
cence with horseradish peroxidase-labeled secondary antibodies.
The used primary antibodies were as follows: TGF-b (Abcam,
ab92486, 1:1,000); TGFBR2 (Santa Cruz, sc-17792, 1:500); b-catenin
(Abcam, ab32572, 1:1,000); CTGF (Santa Cruz, sc-365970, 1:1,000);
IL-1b (Abcam, ab2105, 1:1,000); and ET-1 (Abcam, ab2786,
1:1,000). Secondary antibodies used were as follows: anti-mouse
(Jackson, 515-035-003, 1:5,000) and anti-rabbit (Jackson, 111-035-
045, 1:5,000).
Evans blue staining
An amount of 2 ml of Evans blue solution (0.5% W/V in PBS) was
injected into rat tail veins. After 30 min, rats were euthanized and
perfused with 50 ml PBS to remove intravascular dye. The left lung
was fixed using 4% paraformaldehyde, and images were taken.
Four milliliters of formamide (Fisher Scientific) was added to the
homogenized right lung tissues and incubated at 55°C for 48 h to
extract Evans blue from the tissues. The absorbance at 620 nm of
200 ll clarified supernatant aliquots was measured spectrophoto-
metrically (PerkinElmer VICTOR ×2). Quantification of Evans blue
staining was calculated by measuring the nanogram dye extracted
per milligram tissue.
Statistical analysis
Experimental intervention was randomized. Researchers were
blinded during measurement of serum miR-483 levels, hemodynam-
ics, Fulton index, and wall thickness. The distribution of quantita-
tive variables was assessed for normality by using 1-sample
Kolmogorov–Smirnov test. Equal variance assumptions were tested
with the Brown–Forsythe test. Because serum levels of miR483-3p/-
5p were highly skewed, the difference between IPAH and control
subjects was compared by Kruskal–Wallis U-test or Mann–Whitney
U-test. Other quantitative variables were evaluated with Student’s t-
test or one-way ANOVA. Multiple group testing was adjusted with
the Bonferroni correction. Results are reported as percentages,
median (interquartile range), or means  SEM, as indicated. Two-
tailed P < 0.05 was considered statistically significant. All P-values
are listed in Appendix Table S3. All analyses were performed with
PASW Statistics 18.0 (SPSS Inc).
Data availability
The datasets produced in this study are available in the following
databases:
RNA-Seq data: Gene Expression Omnibus GSE146774 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146774).
Expanded View for this article is available online.
The paper explained
Problem
PH is characterized by increased pulmonary arterial pressure and
small pulmonary vascular remodeling, resulting in right ventricular
hypertrophy and finally heart failure. Mounting evidence indicates
that endothelial dysfunction plays an important role in regulating the
pulmonary arterial remodeling during the pathogenic process of PH.
The current clinical therapy for PH mainly focuses on the dilation of
pulmonary vascular by targeting pathways related to ET-1, NO, and
prostaglandins. However, these treatments are not curative. Micro-
RNAs are small molecules that target mRNA transcripts and inhibit
their expression, which are implicated in EC health and disease. The
current study explores whether miR-483, a protective miR in ECs,
could protect against PH pathogenesis.
Results
Our results showed that miR-483 was decreased in the sera of patients
with IPAH, especially those with more severe disease. RNA-sequencing
and bioinformatics analyses revealed that miR-483 decreases and
targets a panel of PAH-related genes, including TGF-b, TGFBR2, b-
catenin, CTGF, IL-1b, and ET-1. Overexpression of miR-483 in PAECs
inhibits these PAH-related genes. When challenged with MCT or
Sugen + hypoxia, rats with EC-specific miR-483 overexpression exhib-
ited ameliorated PH and reduced right ventricular hypertrophy. More-
over, exogenously delivered miR-483 suppressed PAH-related gene
expression and reversed the PH pathogenesis in rats received MCT.
Impact
Our findings suggest that decreased circulating level of miR-483 is
associated with human IPAH subjects and rodent PH models. Overex-
pression of miR-483 suppresses the PAH-related genes and therefore
tends to protect EC function and ameliorate experimental PH.
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